MNKD MannKind (NASDAQ): Shares slide 36.82% to $3.50 pre-earnings, catalyst to watch
MNKD stock opened the door to volatility after shares fell 36.82% to $3.50 on heavy volume ahead of earnings. MannKind Corporation (MNKD) trades on the NASDAQ in the United States in USD. The company reports results on 26 Feb 2026 at 08:30 AM EST, making tomorrow’s print the immediate catalyst for traders and investors.
MNKD stock: Quick market snapshot
Today’s move pushed MNKD stock from an open of $5.54 to a close of $3.50. Volume surged to 36,450,530 shares versus an average of 3,566,301, giving a relative volume of 10.21. The stock hit a day low of $3.29 and a year low of $3.29, with a year high of $6.51.
MNKD stock: Earnings timing and what to watch
MannKind (MNKD) will report earnings on 26 Feb 2026 at 08:30 AM EST. Investors will watch Afrezza sales, any updated guidance, and commentary on partner programs with United Therapeutics and NRx. Management tone on commercialization and R&D spend should move the shares sharply after the release.
MNKD stock: Financials, valuation and analyst context
Trailing EPS is 0.10 with a trailing PE of 35.00. Market capitalization sits at $1,074,745,000.00. Price to sales is 3.43 and price to free cash flow is 24.89. Wall Street consensus shows multiple buy ratings and a $10.06 average price target from recent coverage. These metrics frame why MNKD stock trades with both upside expectations and valuation risk.
MNKD stock: Technicals and trading signals
Short-term indicators show MNKD stock is deeply oversold. RSI is 19.19 and MACD histogram is negative. Bollinger middle band is $5.60 with upper $6.63 and lower $4.56. The spike in volume and RSI below 20 could invite short-term rebounds, but momentum indicators show downward pressure.
MNKD stock: Risks and near-term opportunities
Risk centers on commercial traction for Afrezza and competitor pipeline moves, including United Therapeutics’ inhaler plans. Insider selling and high short-term volatility increase execution risk. Opportunity lies in improving Afrezza uptake, favorable trial updates, or clearer partner commercialization milestones. Earnings language will shape near-term direction.
MNKD stock: Meyka AI grade and forecast
Meyka AI rates MNKD with a score out of 100: 77.11 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus, and forecasts. Meyka AI’s forecast model projects a yearly price of $6.04, versus the current $3.50, implying an upside of 72.69%. Forecasts are model-based projections and not guarantees.
Final Thoughts
MNKD stock arrives at earnings under heavy selling pressure and elevated volume. The company reports on 26 Feb 2026 at 08:30 AM EST, and Afrezza performance and partner updates will dominate the release. Valuation ratios show a premium versus sales, with a trailing PE of 35.00 and market cap of $1,074,745,000.00, so expectations are priced into the shares. Meyka AI’s model projects a yearly $6.04 target, implying +72.69% from $3.50, but this assumes positive execution and commercial momentum. Given the oversold technicals and concentrated near-term risk, traders should size positions carefully and watch the earnings call transcript for concrete sales and partnership details. For a live tick and additional data, see our MNKD page on Meyka AI’s platform Meyka MNKD page. For market coverage, read related reporting from CNBC and recent trading alerts at Investing.com. Forecasts are model-based projections and not guarantees.
FAQs
When does MannKind report earnings and why does MNKD stock matter?
MannKind reports on 26 Feb 2026 at 08:30 AM EST. MNKD stock often moves on Afrezza sales and partner updates. The earnings call gives fresh revenue and guidance detail that traders use to reprice the shares.
What is Meyka AI’s view on MNKD stock price potential?
Meyka AI’s forecast model projects a yearly price of $6.04, versus the current $3.50, implying about 72.69% upside. This is a model projection and not a guarantee; results depend on execution and earnings details.
What are the main risks for MNKD stock after earnings?
Key risks include weaker Afrezza sales, negative partner developments, continued insider selling, and high volatility. Poor guidance or unclear commercialization plans could push MNKD stock lower quickly.
Which technical signs matter most for MNKD stock near term?
Watch RSI at 19.19 for oversold bounces, volume spikes versus average, and the MACD histogram for momentum shifts. A close above short-term moving averages would reduce immediate downside risk for MNKD stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.